D
D. Simpson
Researcher at North Shore Hospital
Publications - 14
Citations - 1556
D. Simpson is an academic researcher from North Shore Hospital. The author has contributed to research in topics: Ibrutinib & Chronic lymphocytic leukemia. The author has an hindex of 9, co-authored 14 publications receiving 1279 citations.
Papers
More filters
Journal ArticleDOI
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Philippe Moreau,Tamás Masszi,Norbert Grzasko,Nizar J. Bahlis,Markus Hansson,Ludek Pour,Irwindeep Sandhu,Peter Ganly,Bartrum W Baker,Sharon Jackson,Anne-Marie Stoppa,D. Simpson,Peter Gimsing,Antonio Palumbo,Laurent Garderet,Michele Cavo,Shaji Kumar,Cyrille Touzeau,Francis K. Buadi,Jacob P. Laubach,Deborah Berg,J. Lin,Alessandra Di Bacco,Ai Min Hui,Helgi van de Velde,Paul G. Richardson +25 more
TL;DR: The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were limited.
Journal ArticleDOI
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.
Stephen Couban,D. Simpson,Michael J. Barnett,Christopher Bredeson,Lothar Hubesch,Kang Howson-Jan,Tsiporah B. Shore,Irwin Walker,Peter Browett,Hans A. Messner,Tony Panzarella,Jeffrey H. Lipton +11 more
TL;DR: In patients with chronic myeloids leukemia, acute myeloid leukemia, and myelodysplasia undergoing allogeneic transplantation from matched siblings, the use of peripheral blood instead of bone marrow leads to faster hematologic recovery, similar risk of graft-versus-host disease, and improved survival.
Journal ArticleDOI
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam,Judith Trotman,Judith Trotman,Stephen Opat,Jan A. Burger,Gavin Cull,Gavin Cull,David Gottlieb,David Gottlieb,Rosemary Harrup,Rosemary Harrup,Patrick B. Johnston,Paula Marlton,Paula Marlton,Javier Munoz,John F. Seymour,D. Simpson,Alessandra Tedeschi,Rebecca Elstrom,Yiling Yu,Zhiyu Tang,Lynn Han,Jane Huang,William Novotny,Lai Wang,Andrew W. Roberts +25 more
TL;DR: Zanubrutinib demonstrated encouraging activity in CLL/SLL patients, with a low incidence of major toxicities, and definition of the maximum tolerated dose (part 1).
Journal ArticleDOI
Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
Philippe Moreau,Tamas Masszi,Norbert Grzasko,Nizar J. Bahlis,Markus Hansson,Ludek Pour,Irwindeep Sandhu,Peter Ganly,Bartrum W Baker,Sharon Jackson,Anne-Marie Stoppa,D. Simpson,Peter Gimsing,Antonio Palumbo,Laurent Garderet,Michele Cavo,Shaji Kumar,Cyrille Touzeau,Francis K. Buadi,Jacob P. Laubach,Jianchang Lin,Deborah Berg,Alessandra DiBacco,Ai-Min Hui,Paul G. Richardson +24 more
TL;DR: The study met the primary endpoint at the first IA, demonstrating a 35% improvement in PFS with IRd vs Rd, and met the final analysis for PFS, indicating ixazomib may overcome the negative impact of cytogenetic alterations.
Journal ArticleDOI
T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
TL;DR: Pre-transplant alemtuzumab or an earlier version of this molecule, which target CD52+ cells, do appear to be effective in reducing both acute and chronic GVHD, and published studies do show cause for optimism.